D
Denali Therapeutics Inc. DNLI
$15.04 $0.151.01%
Recommendation
Sell
Prev Close
$14.89
Volume
168,885
Avg Vol (90D)
1,022,208
Market Cap
$2.16B
Dividend & Yield
--
52-Week Range
$14.01 - $33.33
P/E (TTM)
--
EPS (TTM)
-$2.58
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Denali Therapeutics (DNLI, $15.95) RSI Indicator left the oversold zone on March 12, 2025
3/13/2025 - Tickeron - Stocks
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.9% Following Analyst Downgrade
3/11/2025 - MarketBeat
Bank of America Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $28.00
3/11/2025 - MarketBeat
Denali Therapeutics (DNLI, $14.95) Stochastic Oscillator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Denali Therapeutics (DNLI, $14.95) RSI Indicator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Denali Therapeutics (DNLI, $14.95) RSI Indicator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Denali Therapeutics (DNLI, $14.95) Stochastic Oscillator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Denali Therapeutics price target lowered by $2 at BofA, here's why
3/10/2025 - The Fly
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)
3/10/2025 - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Now Covered by Analysts at Morgan Stanley
3/8/2025 - MarketBeat
Denali Therapeutics (DNLI, $16.69) RSI Indicator left the oversold zone on March 07, 2025
3/8/2025 - Tickeron - Stocks
Denali Therapeutics assumed with an Overweight at Morgan Stanley
3/7/2025 - TipRanks Financial Blog
Denali Therapeutics assumed with an Overweight at Morgan Stanley
3/7/2025 - The Fly
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)
3/7/2025 - TipRanks Financial Blog
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Candriam S.C.A.
3/7/2025 - MarketBeat
Denali Therapeutics' (DNLI) "Buy" Rating Reaffirmed at B. Riley
3/6/2025 - MarketBeat
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
3/6/2025 - Benzinga
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
3/5/2025 - TipRanks Financial Blog
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
3/5/2025 - The Fly
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)
3/5/2025 - Ticker Report
Denali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low on Analyst Downgrade
3/5/2025 - MarketBeat
Denali Therapeutics price target lowered by $3 at B. Riley, here's why
3/5/2025 - The Fly
The Implied Analyst 12-Month Target For VB
3/5/2025 - ETF Channel
Oppenheimer Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $42.00
3/3/2025 - MarketBeat
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos' Investments in 2025?
3/3/2025 - Insider Monkey
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$495.23M
EBIT (TTM)
-$501.88M
Net Income (TTM)
-$422.77M
Balance Sheet
Total Assets (Q)
$1.37B
Total Debt (Q)
$54.32M
Total Liabilities (Q)
$144.50M
Book Value Per Share (Q)
$8.53
Cash Flow
Cash from Operations (TTM)
-$347.69M
Cash from Investing (TTM)
-$88.76M
Cash from Financing (TTM)
$484.30M
Net Change in Cash (TTM)
$47.85M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.46
7-Day Total Return
-7.79%
30-Day Total Return
-36.26%
60-Day Total Return
-34.57%
90-Day Total Return
-42.10%
Year to Date Total Return
-27.88%
1-Year Total Return
-23.90%
2-Year Total Return
-36.23%
3-Year Total Return
-48.17%
5-Year Total Return
5.85%
52-week Low
Mar 04, 2025 - $14.01
52-week High
Nov 11, 2024 - $33.33
Valuation
Market Cap
$2.16B - Mid Cap
Enterprise Value
$1.02B
Price/Sales (TTM)
--
Price/Book (Q)
1.75
Dividends and Shares
Shares Outstanding
170.09M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.denalitherapeutics.com
Phone Number
650 866 8548
Address
161 Oyster Point Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage... more
NASDAQ 03/14/2025 12:42PM Eastern Quotes delayed
Weiss Ratings